Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin

Japanese Journal of Cancer Research

Volumn 89, Issue 10, 1998, Pages 1061-1066

  Noguchi, Toshihiro ^a   Ichii, Shinji ^a   Morisada, Shinya ^a   Yamaoka, Takashi ^a   Yanagi, Yoshikazu ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Active metabolite; Amrubicin; Anthracycline; SM 5887; Tissue distribution

Indexed keywords

AMRUBICIN; AMRUBICINOL; ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031757797     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00497.x     Document Type: Article

References (22)

1. Ishizumi, K., Ohashi, N. and Tanno, N. Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J. Org. Chem., 52, 4477-4485 (1987).
2. Morisada, S., Yanagi, Y., Noguchi, T., Kashiwazaki, Y. and Fukui, M. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn. J. Cancer Res., 80, 69-76 (1989).
3. Yokota, S., Negoro, S., Yana, T., Takada, Y., Fukuoka, M. and The West Japan Lung Cancer Group. Phase II study of amrubicin (SM-5887), a novel 9-aminoanthracycline, in previously untreated patients with extensive-stage small-cell lung cancer (ES-SCLC): a trial of The West Japan Lung Cancer Group. 8th World Conference on Lung Cancer, A1576 (1997).
4. Hiraki, S., Shinkai, T., Furuse, K., Fukuoka, M., Ohnoshi, T., Kimura, I. and The SM-5887 Lung Cancer Study Group. A phase II of SM-5887, a novel 9-aminoanthracycline, for non-small cell lung cancer. 18th International Congress of Chemotherapy, #726 (1993).
5. Yesair, W., Schwartzbach, E., Shuck, D., Denine, E. P. and Asbell, A. Comparative pharmacokinetics of daunomycin and adriamycin in several animal species. Cancer Res., 32, 1177-1183 (1972).
6. Yamaoka, T., Hanada, M., Ichii, S., Morisada, S., Noguchi, T. and Yanagi, Y. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn. J. Cancer Res., 89, 1061-1067 (1998).
7. Kuffel, J., Reid, M. and Ames, M. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother. Pharmacol., 30, 51-57 (1992).
8. Ozols, F., Willson, V., Weltz, D., Grotzinger, R., Myers, E. and Young, C. Inhibition of human ovarian cancer colony formation by adriamycin and its metabolites. Cancer Res., 40, 4109-4112 (1980).
9. Yesair, D., Thayer, P., McNitt, S. and Teague, K. Comparative uptake, metabolism and retention of anthracyclines by tumors growing in vitro and in vivo. Eur. J. Cancer, 16, 901-907 (1980).
10. Toffolli, G., Corona, G., Simone, F., Gigante, M., Angeli, S. and Boiocchi, M. Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines. Int. J. Cancer, 67, 129-137 (1996).
11. Matsushita, Y., Iguchi, H., Kiyosaki, T., Tone, H. and Ishikura, T. A high performance liquid chromatographic method of analysis of 4′-O-tetrahydropyranyladriamycin and their metabolites in biological samples. J. Antibiot., 36, 880-886 (1983).
12. Iguchi, H., Tone, H., Ishimura, T., Takeuchi, T. and Umezawa, H. Pharmcokinetics and disposition of 4′-O-tetrahydropyranyladriamycin in mice by HPLC analysis. Cancer Chemother. Pharmacol., 15, 132-140 (1985).
13. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodyn., 4, 879-885 (1981).
14. Cusack, J., Young, P. and Olson, D. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat. Cancer Chemother. Pharmacol., 35, 213-218 (1995).
15. Reid, M., Pendergrass, W., Krailo, D., Hammond, D. and Ames, M. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children's Cancer Study Group report. Cancer Res., 50, 6525-6528 (1990).
16. Zanette, L., Zucchetti, M., Freshi, A., Erranti, D., Tirelli, U. and D'Incalci, M. Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemother. Pharmacol., 25, 445-448 (1990).
17. Boven, E., Jong, J., Kuiper, M., Bast, A. and Vijgh, F. Relationship between the tumor tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. Eur. J. Cancer, 32A, 1382-1387 (1996).
18. Shinkai, H., Takahashi, H., Miyamoto, K., Uchida, T. and Tokiwa, T. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and Adriamycin in tumor-bearing mice. Cancer Chemother. Pharmacol., 38, 417-424 (1996).
19. Noguchi, T., Ichii, S., Morisada, S., Yamaoka, T. and Yanagi, Y. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn. J. Cancer Res., 89, 1055-1060 (1998).
20. Jong, J., Schoofs, R., Snabilie, M., Bast, A. and Vijgh, F. The role of biotransformation in anthracycline-induced cardiotoxicity in mice. J. Pharmacol. Exp. Ther., 266, 1312-1320 (1993).
21. Cusack, J., Mushlin, S., Vouleilis, D., Li, X., Boucek, J. and Olson, D. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol. Appl. Pharmacol., 118, 177-185 (1993).
22. Suzuki, T., Minamide, S., Iwasaki, T., Yamamoto, H. and Kanda, H. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest. New Drugs, 15, 219-225 (1997).